Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | 2021
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis
Abstract
Lefamulin is a novel IV and oral pleuromutilin recently approved for the treatment of community‐acquired bacterial pneumonia (CABP). Given that renal comorbidities are common in patients admitted for CABP, understanding the pharmacokinetics of lefamulin in the face of severe renal impairment, including those requiring hemodialysis, is needed.